急性冠脉综合征患者CYP2C19基因多态性与氯吡格雷疗效的关系(5)
[17] Chen K， Zhang R， Liu H， et al. Impact of the CYP2C19 Gene Polymorphism on Clopidogrel Personalized Drug Regimen and the Clinical Outcomes. Clinical Laboratory， 2016， 62(9)：1773-1780.
[18] Charfi R， Mzoughi K， Boughalleb M， et al. Response to clopidogrel and of the cytochrome CYP2C19 genepolymorphism. La Tunisie medicale， 2018， 96(3)：209-218.
[19] Notarangelo MF， Bontardelli F， Merlini PA. Genetic and nongenetic factors influencing the response to clopidogrel. Journal of Cardiovascular Medicine， 2013， 14(14 Suppl 1)：S1-S7.
[20] Bouman HJ， Sch?mig E， Werkum JWV， et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nature Medicine， 2011， 17(1)：110-116.
[21] Calderón-Cruz B， Rodríguez-Galván K， Manzo-Francisco LA， et al. C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention. Thrombosis Research， 2015， 136(5)：894-898.
[收稿日期：2019-06-21], http://www.100md.com(王光亮 林爽 吴雪梅)
[18] Charfi R， Mzoughi K， Boughalleb M， et al. Response to clopidogrel and of the cytochrome CYP2C19 genepolymorphism. La Tunisie medicale， 2018， 96(3)：209-218.
[19] Notarangelo MF， Bontardelli F， Merlini PA. Genetic and nongenetic factors influencing the response to clopidogrel. Journal of Cardiovascular Medicine， 2013， 14(14 Suppl 1)：S1-S7.
[20] Bouman HJ， Sch?mig E， Werkum JWV， et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nature Medicine， 2011， 17(1)：110-116.
[21] Calderón-Cruz B， Rodríguez-Galván K， Manzo-Francisco LA， et al. C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention. Thrombosis Research， 2015， 136(5)：894-898.
[收稿日期：2019-06-21], http://www.100md.com(王光亮 林爽 吴雪梅)